Correlation of genome-wide DNA CNAs and acquired mutations or genomic rearrangements with ROSE gene-expression cluster groups
| . | R1 . | R2 . | R3 . | R4 . | R5 . | R6 . | R7 . | R8 . | Total . | FET (P)* . | Comments . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases evaluated | 20 | 22 | 12 | 13 | 10 | 21 | 76 | 24 | 198 | ||
| 1q (gain)† | 0 | 14 | 1 | 1 | 0 | 0 | 1 | 0 | 17 | < .0001 | R2 contains TCF3-PBX1 |
| IKZF1 | 1 | 0 | 0 | 3 | 3 | 6 | 24 | 22 | 59 | < .0001 | |
| CDKN2A/B | 4 | 9 | 11 | 11 | 1 | 5 | 40 | 15 | 96 | < .0001 | |
| TCF3 | 0 | 14 | 0 | 0 | 2 | 2 | 2 | 0 | 20 | < .0001 | R2 contains TCF3-PBX1 |
| ERG | 0 | 0 | 0 | 1 | 0 | 8 | 0 | 0 | 9 | < .0001 | |
| VPREB1 | 0 | 0 | 0 | 5 | 1 | 8 | 23 | 14 | 51 | < .0001 | |
| B-cell pathway | 5 | 17 | 5 | 12 | 4 | 12 | 54 | 23 | 132 | < .0001 | |
| B pathway w/VPREB1 | 5 | 17 | 5 | 12 | 5 | 14 | 56 | 24 | 138 | < .0001 | |
| PAX5 | 1 | 9 | 4 | 11 | 0 | 3 | 28 | 7 | 63 | < .0001 | |
| EBF1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 9 | 13 | .0001 | |
| TBL1XR1 | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 5 | .0005 | |
| NUP160-PTPRJ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | .0028 | |
| ETV6 | 1 | 0 | 2 | 2 | 4 | 1 | 14 | 0 | 24 | .0055 | |
| IL3RA-CSF2RA | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 7 | 14 | .0064 | High CRLF2 expression |
| DMD | 0 | 5 | 1 | 0 | 2 | 3 | 3 | 0 | 14 | .0109 | |
| C20orf94 | 0 | 0 | 0 | 1 | 1 | 0 | 7 | 7 | 16 | .0102 | |
| RAG1/2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 7 | .0144 | |
| ADD3 | 0 | 1 | 0 | 2 | 0 | 0 | 7 | 7 | 17 | .0156 | |
| NF1 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 5 | .0269 | |
| ARMC2-SESN1 | 0 | 2 | 0 | 1 | 2 | 0 | 3 | 5 | 13 | .0297 | |
| JAK1 (mutation) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | .9448 | High CRLF2 expression |
| JAK2 (mutation) | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 11 | 16 | < .0001 | High CRLF2 expression |
| CRLF2 rearrangement: IGH@-CRLF2 | 0 | 0 | 0 | 1 | 0 | 0 | 7 | 11 | 19 | < .0001 | High CRLF2 expression |
| CRLF2 rearrangement: P2RY8-CRLF2 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 11 | .0041 | High CRLF2 expression |
| . | R1 . | R2 . | R3 . | R4 . | R5 . | R6 . | R7 . | R8 . | Total . | FET (P)* . | Comments . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases evaluated | 20 | 22 | 12 | 13 | 10 | 21 | 76 | 24 | 198 | ||
| 1q (gain)† | 0 | 14 | 1 | 1 | 0 | 0 | 1 | 0 | 17 | < .0001 | R2 contains TCF3-PBX1 |
| IKZF1 | 1 | 0 | 0 | 3 | 3 | 6 | 24 | 22 | 59 | < .0001 | |
| CDKN2A/B | 4 | 9 | 11 | 11 | 1 | 5 | 40 | 15 | 96 | < .0001 | |
| TCF3 | 0 | 14 | 0 | 0 | 2 | 2 | 2 | 0 | 20 | < .0001 | R2 contains TCF3-PBX1 |
| ERG | 0 | 0 | 0 | 1 | 0 | 8 | 0 | 0 | 9 | < .0001 | |
| VPREB1 | 0 | 0 | 0 | 5 | 1 | 8 | 23 | 14 | 51 | < .0001 | |
| B-cell pathway | 5 | 17 | 5 | 12 | 4 | 12 | 54 | 23 | 132 | < .0001 | |
| B pathway w/VPREB1 | 5 | 17 | 5 | 12 | 5 | 14 | 56 | 24 | 138 | < .0001 | |
| PAX5 | 1 | 9 | 4 | 11 | 0 | 3 | 28 | 7 | 63 | < .0001 | |
| EBF1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 9 | 13 | .0001 | |
| TBL1XR1 | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 5 | .0005 | |
| NUP160-PTPRJ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | .0028 | |
| ETV6 | 1 | 0 | 2 | 2 | 4 | 1 | 14 | 0 | 24 | .0055 | |
| IL3RA-CSF2RA | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 7 | 14 | .0064 | High CRLF2 expression |
| DMD | 0 | 5 | 1 | 0 | 2 | 3 | 3 | 0 | 14 | .0109 | |
| C20orf94 | 0 | 0 | 0 | 1 | 1 | 0 | 7 | 7 | 16 | .0102 | |
| RAG1/2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 7 | .0144 | |
| ADD3 | 0 | 1 | 0 | 2 | 0 | 0 | 7 | 7 | 17 | .0156 | |
| NF1 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 5 | .0269 | |
| ARMC2-SESN1 | 0 | 2 | 0 | 1 | 2 | 0 | 3 | 5 | 13 | .0297 | |
| JAK1 (mutation) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | .9448 | High CRLF2 expression |
| JAK2 (mutation) | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 11 | 16 | < .0001 | High CRLF2 expression |
| CRLF2 rearrangement: IGH@-CRLF2 | 0 | 0 | 0 | 1 | 0 | 0 | 7 | 11 | 19 | < .0001 | High CRLF2 expression |
| CRLF2 rearrangement: P2RY8-CRLF2 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 11 | .0041 | High CRLF2 expression |